Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer
Tackling urgent questions in EGFRm NSCLC – 'the issue is treatment sequence'
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
NSCLC: the increasing need for PD-L1 testing
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr